Melatonin attenuates methamphetamine-induced disturbances in mitochondrial dynamics and degeneration in neuroblastoma SH-SY5Y cells
Related Experiment Video
Updated: May 9, 2026

Histological Examination of Mitochondrial Morphology in a Parkinson's Disease Model
Published on: June 23, 2023
Arisa Parameyong1, Komgrid Charngkaew, Piyarat Govitrapong
1Research Center for Neuroscience, Institute of Molecular Biosciences, Mahidol University, Salaya, Nakhonpathom, Thailand.
Abstract:
Methamphetamine (METH) is a psychostimulant drug that can cause toxicity and degeneration in the brain. The toxicity due to METH involves multiple pathways, including the mitochondrial-dependent death pathway. Several pieces of evidence have emphasized that the fragmentation of mitochondria into smaller structures plays some role in the cell-death process. In this study, we investigated the role of mitochondrial dynamics in METH-induced toxicity in human dopaminergic neuroblastoma SH-SY5Y cultured cell lines. In addition, the protective effect of melatonin against METH-induced toxicity was investigated. Our results show that METH significantly decreased cell viability and increased the levels of the mitochondrial fission protein, Fis1 and the Drp1 oligomer. However, the levels of the mitochondrial fusion proteins OPA1 and Mfn1 did not change in METH-treated cells. Melatonin can reverse the toxic effects of the METH-induced reduction in cell viability and the production of the Fis1 protein and the Drp1 oligomer. Moreover, the morphological alteration of mitochondria was investigated in METH-treated cells in the presence of melatonin using transmission electron microscopy (TEM). At 24 hr after METH exposure, typical cell shrinkage was observed in SH-SY5Y cells. Mitochondria were fragmented into small globular structures in a large proportion of METH-treated cells, but tubular networks of mitochondria were present in large proportions of control-untreated cells and METH-treated cells in the presence of melatonin. The results of the present study demonstrate the potential of melatonin to reduce cell death and restore mitochondrial function in neurons affected by METH-induced toxicity.
Insights
Methamphetamine (METH) causes neurotoxicity by disrupting mitochondrial dynamics, leading to cell death. Melatonin treatment protected against METH-induced toxicity by restoring mitochondrial function and cell viability.
Area of Science:
- Neuroscience
- Cell Biology
- Pharmacology
Background:
- Methamphetamine (METH) is a neurotoxic psychostimulant.
- METH-induced toxicity involves mitochondrial dysfunction and cell death pathways.
- Mitochondrial dynamics, including fission and fusion, are crucial for cellular health.
Purpose of the Study:
- To investigate the role of mitochondrial dynamics in METH-induced neurotoxicity.
- To examine the protective effects of melatonin against METH toxicity in human dopaminergic neuroblastoma cells.
- To elucidate the mechanisms underlying METH toxicity and melatonin's protective action.
Main Methods:
- Utilized human dopaminergic neuroblastoma SH-SY5Y cell lines.
- Assessed cell viability and protein levels of mitochondrial dynamics regulators (Fis1, Drp1, OPA1, Mfn1).
- Employed transmission electron microscopy (TEM) to analyze mitochondrial morphology.
Main Results:
- METH significantly reduced cell viability and increased mitochondrial fission proteins (Fis1, Drp1 oligomer).
- Mitochondrial fusion proteins (OPA1, Mfn1) levels remained unchanged after METH treatment.
- Melatonin reversed METH-induced cell death, restored cell viability, and normalized mitochondrial morphology, preventing fragmentation.
Conclusions:
- METH-induced neurotoxicity is associated with increased mitochondrial fission.
- Melatonin exhibits neuroprotective effects against METH toxicity by modulating mitochondrial dynamics.
- Melatonin holds potential for mitigating METH-induced neuronal damage and restoring mitochondrial function.
Related Concept Videos
Sedatives and Hypnotics Drugs: Miscellaneous Agents
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
Management of Insomnia
Drugs Affecting Neurotransmitter Synthesis
Mitochondrial Membranes
